Artículo

Disaccharides obtained from carrageenans as potential antitumor agents

Calvo, Gustavo Hernán Icon; Cosenza, Vanina Icon; Saenz, Daniel Alberto Icon; Navarro, Diego Alberto Icon; Stortz, Carlos Arturo Icon; Céspedes, Mariela Anahí ; Mamone, Leandro Ariel Icon; Casas, Adriana Gabriela Icon; Di Venosa, Gabriela Mariana Icon

Otros responsables

Fecha

12/2019

Editorial

Nature Publishing Group

Revista

Scientific Reports

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

2045-2322

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Carrageenans are sulfated galactans found in certain red seaweeds with proven biological activities. In this work, we have prepared purified native and degraded κ-, ι-; and λ-carrageenans, including the disaccharides (carrabioses) and disaccharide-alditols (carrabiitols) from seaweed extracts as potential antitumor compounds and identified the active principle of the cytotoxic and potential antitumor properties of these compounds. Both κ and ι-carrageenan, as well as carrageenan oligosaccharides showed cytotoxic effect over LM2 tumor cells. Characterized disaccharides (carrabioses) and the reduced product carrabiitols, were also tested. Only carrabioses were cytotoxic, and among them, κ-carrabiose was the most effective, showing high cytotoxic properties, killing the cells through an apoptotic pathway. In addition, the cells surviving treatment with κ-carrabiose, showed a decreased metastatic ability in vitro, together with a decreased cell-cell and cell-matrix interactions, thus suggesting possible antitumor potential. Overall, our results indicate that most cytotoxic compounds derived from carrageenans have lower molecular weights and sulfate content. Potential applications of the results emerging from the present work include the use of disaccharide units such as carrabioses coupled to antineoplasics in order to improve its cytotoxicity and antimetastatic properties, and the use of ι-carrageenan as adjuvant or carrier in anticancer treatments.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa